postoperative nausea
Conditions
Interventions
Oliceridine group:oliceridine-based patient-controlled intravenous analgesia
Sufentanil group:Sufentanil-based patient-controlled intravenous analgesia
Sponsors
Xuanwu Hospital Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Patients scheduled for cerebellopontine-angle surgery with planned postoperative intravenous patient-controlled analgesia. 2.Aged 18–65 years, either sex. 3.ASA I~III; 4.Provision of written informed consent.
Exclusion criteria
Exclusion criteria: 1.Opioid-tolerant patients (continuous opioid use =1 week with daily oral morphine equivalent =50 mg, oxycodone =30 mg, or equipotent doses of other opioids). 2.Severe cardiac, pulmonary, hepatic, renal, vascular, neurologic, hematologic, gastrointestinal, or endocrine disease. 3.Requirement for postoperative endotracheal intubation and ICU admission. 4.Body-mass index (BMI) =18.5 or =30 kg·m?². 5.Participation in another clinical trial within the preceding 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of postoperative nausea; | — |
Secondary
| Measure | Time frame |
|---|---|
| respiratory depression;Gastrointestinal function score;The situation of using antiemetic drugs as a remedial measure;Static and dynamic pain VRS scores;The incidence of vomiting; | — |
Countries
China
Contacts
Public ContactXiao Wei
Xuanwu Hospital Capital Medical University
Outcome results
None listed